Some content of this application is unavailable at the moment.
If this situation persist, please contact us atFeedback&Contact
1. (WO2015042807) FULLY HUMANIZED ANTI-CD20 MONOCLONAL ANTIBODY AND USES THEREOF
Latest bibliographic data on file with the International Bureau   

Pub. No.: WO/2015/042807 International Application No.: PCT/CN2013/084203
Publication Date: 02.04.2015 International Filing Date: 25.09.2013
IPC:
C07K 16/30 (2006.01) ,C12N 15/13 (2006.01) ,C12N 15/63 (2006.01) ,A61K 39/395 (2006.01) ,A61P 35/00 (2006.01) ,A61P 37/00 (2006.01)
C CHEMISTRY; METALLURGY
07
ORGANIC CHEMISTRY
K
PEPTIDES
16
Immunoglobulins, e.g. monoclonal or polyclonal antibodies
18
against material from animals or humans
28
against receptors, cell surface antigens or cell surface determinants
30
from tumour cells
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
11
DNA or RNA fragments; Modified forms thereof
12
Genes encoding animal proteins
13
Immunoglobulins
C CHEMISTRY; METALLURGY
12
BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
N
MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15
Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09
Recombinant DNA-technology
63
Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
K
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39
Medicinal preparations containing antigens or antibodies
395
Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35
Antineoplastic agents
A HUMAN NECESSITIES
61
MEDICAL OR VETERINARY SCIENCE; HYGIENE
P
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37
Drugs for immunological or allergic disorders
Applicants:
北京安保康生物医药科技有限公司 BEIJING ABCO PHARMACEUTICALS CO., LTD. [CN/CN]; 中国北京市北京经济技术开发区地盛东路1号1幢A202 Suite 202, Build One, #1 Disheng East Road Beijing Economic and Technological Development Zone Beijing 100176, CN
Inventors:
冯晓 FENG, Xiao; US
Agent:
北京三友知识产权代理有限公司 BEIJING SANYOU INTELLECTUAL PROPERTY AGENCY LTD.; 中国北京市 金融街35号国际企业大厦A座16层 F16, Block A, Corporate Square, No.35 Jinrong Street Beijing 100033, CN
Priority Data:
Title (EN) FULLY HUMANIZED ANTI-CD20 MONOCLONAL ANTIBODY AND USES THEREOF
(FR) ANTICORPS MONOCLONAL ANTI-CD20 TOTALEMENT HUMANISÉ ET SES UTILISATIONS
(ZH) 抗CD20的全人源单克隆抗体及其应用
Abstract:
(EN) Provided is a fully humanized anti-CD20 monoclonal antibody, which is prepared by human hybridoma technology. The antibody has excellent affinity and specificity, and a significant cytotoxic effect on lymphoma cells, and so can be used for the preparation of pharmaceutical compositions for treating or diagnosing diseases such as non-Hodgkin lymphoma, B cell lymphoma, rheumatic and rheumatoid diseases, systemic lupus erythematosus, immune thrombocytopenic purpura and multiple sclerosis.
(FR) La présente invention concerne un anticorps monoclonal anti-CD20 totalement humanisé, qui est préparé par technologie d’hybridome humain. L’anticorps a d’excellentes propriétés d'affinité et de spécificité, et un effet de cytotoxicité significatif sur les cellules de lymphome, et peut donc être utilisé pour la préparation de compositions pharmaceutiques pour traiter ou diagnostiquer des maladies telles qu’un lymphome non hodgkinien, un lymphome à cellules B, des maladies rhumatismales et rhumatoïdes, le lupus érythémateux disséminé, le purpura thrombopénique immunologique et la sclérose en plaques.
(ZH) 本发明提供了一种抗CD20的全人源单克隆抗体,其通过人杂交瘤技术制备。所述抗体具有优异的亲和力和特异性,对淋巴瘤细胞具有显著的细胞毒功效,可用于制备治疗或诊断非霍奇金氏淋巴瘤、B细胞淋巴瘤、风湿性和类风湿性疾病、系统性红斑狼疮、免疫性血小板减少性紫癜和多发性硬化症等疾病的药物组合物。
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW
African Regional Intellectual Property Organization (ARIPO) (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Office (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (EPO) (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG)
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)